Results 181 to 190 of about 113,281 (294)

MicroRNAs modulated by DPP-4 inhibitor and bedtime NPH insulin therapy in individuals with type 2 diabetes. [PDF]

Front Endocrinol (Lausanne)
Santos AS, Bando SY, Correa Giannella MLC, da Silva MER.   +3 more
europepmc   +1 more source

Efficacy and Safety of Intensifying Once‐Weekly Insulin Icodec Treatment With Once‐Weekly Semaglutide in Adults With Type 2 Diabetes: A Single‐Arm, Open‐Label, Treat‐to‐Target, Phase 3b Trial (ONWARDS 8)

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To investigate the efficacy and safety of intensifying once‐weekly insulin icodec (icodec) with once‐weekly semaglutide in adults with type 2 diabetes (T2D). Materials and Methods ONWARDS 8 was a single‐arm, open‐label, treat‐to‐target, Phase 3b trial comprising a 26‐week icodec run‐in period and a 26‐week semaglutide intensification ...
Krzysztof Strojek, Andreas Liebl, Neha Narendra Mumbaikar, Stinne Byrholdt Søgaard, Sara Kehlet Watt, Athena Philis‐Tsimikas   +5 more
wiley   +1 more source

Exercise or Fasting in Individuals With Type 2 Diabetes Receiving Once‐Weekly Basal Insulin Icodec

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To investigate glucose levels and hypoglycaemia risk during exercise or fasting in adults with type 2 diabetes (T2D) treated with once‐weekly basal insulin icodec. Materials and Methods Thirty basal insulin‐treated, physically active individuals with T2D (18–75 years, glycated haemoglobin ≤ 75 mmol/mol, peak oxygen uptake > 20 mL/kg/min ...
Thomas R. Pieber, Harpreet S. Bajaj, Gabriele Fluhr, Klara R. Klein, Thaís M. Pagliaro Rocha, Harald Sourij, Eva Svehlikova, Keerthana Udupa, Sara K. Watt, Maria Willerslev‐Olsen, Rasmus Ribel‐Madsen   +10 more
wiley   +1 more source

Case Report: NEUROD1 c.-108G>C mutation in a ketosis-prone MODY6 patient: implications for genetic testing and DPP-4 inhibitor therapy. [PDF]

Front Endocrinol (Lausanne)
Shao Z, Xu L.
europepmc   +1 more source

Potential Mediators of Efpeglenatide's Cardiovascular Benefit: An Exploratory Analysis of the AMPLITUDE‐O Trial

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims In the AMPLITUDE O trial, efpeglenatide reduced major cardiovascular events by 27% in 4076 individuals with Type 2 diabetes and established cardiovascular or kidney disease compared to placebo during a median follow‐up of 1.81 years. This exploratory mediation analysis evaluates the degree to which changes in measured clinical variables ...
Daniel Raaschou‐Oddershede, Christine R. Schwarz, Tanya Kovalova, Kelley R. Branch, Stefano Del Prato, Carolyn S. P. Lam, Renato D. Lopes, Richard Pratley, Julio Rosenstock, Naveed Sattar, Hertzel C. Gerstein   +10 more
wiley   +1 more source

Triple oral therapy with metformin, DPP-4 inhibitor, and SGLT2 inhibitor for adults with type 2 diabetes: Consensus recommendations of a Chinese expert panel (version 2025). [PDF]

Diabetes Obes Metab
Yu M, Wang T, Xu C, Bi Y, Gao L, Wang G, Xiang G, Xue Y, Yang T, Kang D, Zhou Z, Guo L, Xiao X, Steering Committee, Development Group, Diabetes Committee of the Chinese Research Hospital Association.   +15 more
europepmc   +1 more source

The sorting nexin Snx21 promotes flotillin‐mediated endocytosis

The FEBS Journal, EarlyView.
In this study, we describe a novel function of the previously uncharacterized Snx21 protein as a specific positive regulator of flotillin‐mediated endocytic trafficking. Snx21 is recruited to endosomal membranes via binding to PI(3)P, and it colocalizes with flotillins on the surface of late endosomes.
Tamás Maruzs, Enikő Lakatos, Dalma Feil‐Börcsök, Gábor Juhász, Regina Mező, Asha Kiran Maddali, András Blastyák, Aladár Pettkó‐Szandtner, Hajnalka Laczkó‐Dobos, Gábor Juhász   +9 more
wiley   +1 more source

Euglycemic DKA in a DPP-4 inhibitor patient following traumatic brain injury: A complex ICU glucose management challenge. [PDF]

Medicine (Baltimore)
Shammas I, Seyaj M, Altell K, Sobeih R, Asafrah L, Burqan M, Abuhalawa M, Shahateet M, Itkaidek S.   +8 more
europepmc   +1 more source

Preventive Effect of Mineralocorticoid Receptor Antagonists Against Proteinuria Induced by Atezolizumab Plus Bevacizumab Therapy in Hepatocellular Carcinoma: A Multicenter Retrospective Study

Hepatology Research, EarlyView.
Mineralocorticoid receptor antagonists are known to reduce proteinuria in chronic kidney disease, but their effectiveness in preventing bevacizumab‐related proteinuria has not been well established. In the present multi‐institutional retrospective study, we found that these agents significantly delay the onset of moderate or higher grade proteinuria ...
Tomoki Hori, Kazuhiro Yamamoto, Hiroshi Aoi, Yusuke Koizumi, Makoto Kuromatsu, Aiko Fukui, Hiroyo Okamoto, Atsushi Hirata, Kentaro Shinmori, Yuki Imanaka, Miyu Namba, Keisuke Nakanishi, Syunsuke Kitamura, Hideo Tsushima, Ikuko Yano, Kei Moriya, Masaru Matsui, Shigeki Ikushima   +17 more
wiley   +1 more source

A Comparison of SGLT2 or DPP-4 Inhibitor Monotherapy vs Placebo for Type 2 Diabetes in Adolescents vs Young Adults. [PDF]

J Endocr Soc
Laffel LM, Danne T, Klingensmith GJ, Schueler E, Tartakovsky I, Nessralla L, Zeitler P, Willi S.   +7 more
europepmc   +1 more source